
Sign up to save your podcasts
Or


Send us a text
This discussion features Dr. Clyde Wright, Professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine, who studies perinatal innate immunity and neonatal lung injury. He highlights the rapid rise of acetaminophen as the most commonly used medication for ductal closure in preterm infants despite limited long-term safety data. Dr. Wright explains how acetaminophen metabolism via CYP2E1 produces a reactive metabolite that may affect mitochondrial function in developing lung cells, prompting consideration beyond hepatic toxicity markers. He encourages clinicians to remain judicious, especially outside optimal treatment windows, and calls for research incorporating respiratory outcomes and nuanced, individualized risk–benefit discussions at the bedside.
Support the show
As always, feel free to send us questions, comments, or suggestions to our email: [email protected]. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.
Enjoy!
By Ben Courchia & Daphna Yasova Barbeau4.9
151151 ratings
Send us a text
This discussion features Dr. Clyde Wright, Professor of Pediatrics at Children’s Hospital Colorado and the University of Colorado School of Medicine, who studies perinatal innate immunity and neonatal lung injury. He highlights the rapid rise of acetaminophen as the most commonly used medication for ductal closure in preterm infants despite limited long-term safety data. Dr. Wright explains how acetaminophen metabolism via CYP2E1 produces a reactive metabolite that may affect mitochondrial function in developing lung cells, prompting consideration beyond hepatic toxicity markers. He encourages clinicians to remain judicious, especially outside optimal treatment windows, and calls for research incorporating respiratory outcomes and nuanced, individualized risk–benefit discussions at the bedside.
Support the show
As always, feel free to send us questions, comments, or suggestions to our email: [email protected]. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.
Enjoy!

128 Listeners

3,670 Listeners

2,437 Listeners

56,524 Listeners

268 Listeners

774 Listeners

1,890 Listeners

225 Listeners

236 Listeners

316 Listeners

804 Listeners

4,493 Listeners

41,539 Listeners

61 Listeners

2 Listeners

2 Listeners

8 Listeners

5 Listeners

2 Listeners

0 Listeners